BACKGROUND:Nowadays, most of the studies regarding tissue engineering bone have mostly focused on critical-size bone defects of the backbone; however, there are less studies and reports on its spinal fusion. OBJECTIVE:To explore the feasibility of xenogeneic deproteinized cancelous bone as bone tissue engineering scaffold in the treatment of spinal intertransverse fusion. METHODS:The cancelous part in the distal femur of adult pigs was obtained to prepare xenogeneic deproteinized cancelous bone. After combined with the recombinant human bone morphogenetic protein, the xenogeneic deproteinized cancelous bone was combined with bone marrow mesenchymal stem cels to prepare tissue engineering bone. Twenty-four goats were obtained to prepare intertransverse bone bed, and randomly divided into two groups: observation and control groups. In the observation group, the tissue engineered bone was implanted into the left side, and the xenogeneic deproteinized cancelous bone of recombinant human bone morphogenetic protein was implanted into the right side. In the control group, the autologous iliac bone was implanted into the left side, and xenogenic deproteinization cancelous bone was implanted into the right side. At the 4th, 8th and 12th weeks after implantation, the fusion segment was obtained for gross observation, X-ray observation, histological observation and biomechanical testing. RESULTS AND CONCLUSION:X-ray films showed that the implant materials from these two groups were fixed wel and reliably. At different time points after implantation, the implant materials from each group were al in good position. There were no purulent and necrotic tissues around the material. Soft tissue ingrow and wraping were present. There were no effusions and necrosis surrounding the implant materials. The imaging and histological performance in the tissue engineering bone group outperformed that in the recombinant human bone morphogenetic protein xenogenic deproteinized cancelous bone group and xenogenic deproteinized cancelous bone group, which was the most close to the autogenous bone. At the 12th week after implantation, the maximum bending load in the tissue engineering bone group was the most close to the autogenous iliac bone group. There was no significant difference between these two groups. These results demonstrate that as bone tissue engineering scaffold, xenogenic deproteinized cancelous bone has a certain application feasibility in the treatment of spinal intertransverse fusion.

OBJECTIVE:To establish the quality standard of Gongyanping dispersible tablets.METHODS:Melastoma dodecandrum,Zanthoxylum nitidum and Ficus simplicissima in the formulation was identified by TLC,and the content of gallic acid in gongyanping dispersible tablets was determined by HPLC.RESULTS:The TLC spots were clear,well-isolated and distinctive.The linear range of gallic acid was 0.146 48～2.929 6 ?g(r=0.999 7)and its average recovery was 99.89%(RSD=2.53%,n=6).CONCLUSION:The established quality standard can be used for the quality control of Gongyanping dispersible tablets.

Objective:This study aims to analyze the threshold changes in distortion product otoacoustic emissions（DPOAE） and auditory brainstem response（ABR） in adult Otof-/- mice before and after gene therapy, evaluating its effectiveness and exploring methods for assessing hearing recovery post-treatment. Methods:At the age of 4 weeks, adult Otof-/- mice received an inner ear injection of a therapeutic agent containing intein-mediated recombination of the OTOF gene, delivered via dual AAV vectors through the round window membrane（RWM）. Immunofluorescence staining assessed the proportion of inner ear hair cells with restored otoferlin expression and the number of synapses.Statistical analysis was performed to compare the DPOAE and ABR thresholds before and after the treatment. Results:AAV-PHP. eB demonstrates high transduction efficiency in inner ear hair cells. The therapeutic regimen corrected hearing loss in adult Otof-/- mice without impacting auditory function in wild-type mice. The changes in DPOAE and ABR thresholds after gene therapy are significantly correlated at 16 kHz. Post-treatment,a slight increase in DPOAE was observeds,followed by a recovery trend at 2 months post-treatment. Conclusion:Gene therapy significantly restored hearing in adult Otof-/- mice, though the surgical delivery may cause transient hearing damage. Precise and gentle surgical techniques are essential to maximize gene therapy's efficacy.
Mice ; Animals ; Otoacoustic Emissions, Spontaneous/physiology* ; Hearing/physiology* ; Ear, Inner ; Hearing Loss/therapy* ; Genetic Therapy ; Auditory Threshold/physiology* ; Evoked Potentials, Auditory, Brain Stem/physiology* ; Membrane Proteins